Literature DB >> 3552720

Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.

T Skovsgaard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3552720     DOI： 10.1111/j.1600-0609.1987.tb00018.x

Source DB:  PubMed          Journal:  Eur J Haematol Suppl        ISSN： 0902-4506


× No keyword cloud information.
  3 in total

1.  Phase II study of high-dose aclarubicin in previously treated patients with small-cell lung cancer.

Authors:  P B Jensen; S K Larsen; I Stilbo
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.

Authors:  L N Petersen; P B Jensen; B S Sørensen; S A Engelholm; M Spang-Thomsen
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL).

Authors:  P B Jensen; L Vindeløv; H Roed; E J Demant; M Sehested; T Skovsgaard; H H Hansen
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.